This is the first major breakthrough in 50 years. British researchers have just discovered a new treatment for severe forms ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...

Introduction Despite advancements in asthma management, many patients continue to experience poor disease control, lung function decline, and frequent exacerbations. Clinical remission (CR) has been ...

Researchers assessed patients receiving omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab or tezepelumab for asthma. Adherence was deemed intermittent based on heatmaps. SAN DIEGO ...

In this work, we report our real-life experience with EGPA patients, treated with biologics targeting type 2 (T2)-eosinophilic inflammation (Mepolizumab, Benralizumab, Dupilumab). Interestingly, we ...